What Nvidia, Intel, and AMD Stock Investors Should Know About Recent Top AI Updates
Could Advanced Micro Devices’ recent acquisition be a red flag for Nvdia’s software dominance?
Mindfully Curated
Could Advanced Micro Devices’ recent acquisition be a red flag for Nvdia’s software dominance?
Netflix kicks off earnings season for growth investors on Wednesday. There’s a lot riding on the financial update.
These companies are leading the tech market and could have lucrative futures with their expanding ventures in AI.
The online language learning leader is holding up better than many of its industry peers.
It’s the best of times and worst of times in Hollywood. On one hand, the Writer’s Guild of America strike ended after a 148-day work stoppage,…
Economics may be known as the dismal science, but modern day practitioners sound suspiciously sanguine about America’s ability to sidestep a…
If EVs are the future, drivers didn’t get the memo. People are buying EVs, just not at the hyper-pace most automakers were hoping would be here…
Never, ever question the grit, moxy, and relentlessness of that uniquely American species we call the mall rat. Wall Street legend Carl Icahn bet…
These businesses have bright futures, but you wouldn’t know it from their stocks’ bargain-basement valuations.
The latest twist in this auction is not good news for shareholders.
There might be light at the end of the tunnel. Is INTC stock a buy now?
Ongoing macroeconomic pressures created bearish sentiment in the stock market last month.
These stocks are well-positioned to grow at an impressive pace in the coming years.
Shares in Amazon and Shopify look too good to ignore.
A strong foundation is critical for any portfolio, so beginners should look for great stocks to build with.
Investors can take a hands-off approach and let these ETFs do the heavy lifting.
Nvidia continues to introduce new AI software solutions.
Which of these optical stocks has a brighter future?
AT&T and Verizon have accumulated a huge amount of debt that could threaten their dividend payments.
These two large-cap biopharma companies could have more room to run.